Dr Mitchel Tate : using gene therapy to improve diabetic cardiomyopathy

Dr Mitchel Tate is a research officer in the Heart Failure Pharmacology Laboratory at the Baker Heart and Diabetes Institute. He is currently working on a project, funded by the Diabetes Australia Research Trust, to develop new therapies for diabetes-related heart disease.

Read more

Challenge: can you describe the aim of this project in 10 words? To improve diabetic cardiomyopathy using cardiac-targeted gene therapy. Why gene therapy for cardiomyopathy? There are several advantages of using a gene therapy over a traditional pharmacological approach. Firstly, gene therapy can be organ targeted, or even cell-type targeted (e.g. to the cardiomyocyte), meaning ...

Already a member?

Login to keep reading.

© 2021 the limbic